Health Plan (7.4) 7.4

P-OPS 9 - P&T Committee Membership

Submited by: Tom Goddard

The Basics

This standard defines and constrains the possible composition of the P&T Committee. The parameters for membership include:

  • Diverse specialties representative of the members' needs; and
  • Representation of, or consultation with, specialists as appropriate.
Further, a majority of the voting members must be practicing physicians or pharmacists. At least one of the physicians, and at least one of the pharmacists, must specialize in geriatrics or disabilities. All these clinicians must be appropriately credentialed under URAC standards. Finally, more than half of the practicing clinicians must be independent and conflict-free and not employees of your health plan.

Management Tips

One of the things to think about is what your committee will do if it encounters a need for a specialist that is not represented on the committee. Now matter how you decide to address this likely eventuality, work that into the applicable P&P. 

Accreditation Tips

Desktop Review
In addition to the applicable P&P, submit a list of P&T committee members, their qualifications, and sample P&T Committee meeting minutes.
Validation Review
The onsite review will focus on an interview of staff members supporting the P&T Committee.

  • Health Plan (7.4) 7.4 / 02.19.2021

    P-OPS 12 - Breach Handling

    This standard outlines the requirements for your organization when a privacy breach is discovered. The process must include:Recording the date your organization knew or should have known of the breach;Notifying the privacy and security official(s);Determining whether a breach actually occurred;Once it's determined that a breach did, in fact, occur, Recording the date of the breach;Mitigating the c...

  • Health Plan (7.4) 7.4 / 02.19.2021

    P-OPS 11 - Oversight of Automated Review of Pharmacy Non-Certifications

    If your organization conducts automated review in connection with drug management, you must have written P&Ps that describe the oversight mechanism for such automated review. That oversight must be conducted by both a senior clinician and a clinical oversight body. That oversight body can be, but need not be, the P&T Committee.The oversight of automated review must be active and well-documented. O...

  • Health Plan (7.4) 7.4 / 02.19.2021

    P-OPS 10 - Economic Formulary Considerations

    In order to assure that cost issues do not supercede clinical issues, this standard prohibits consideration of economic factors of a medication before its safety efficacy, therapeutic appropriateness, and side effects have been established. Once those issues have been considered, it is appropriate to evaluate equivalent alternative medications and therapies in terms of their impact on health costs...